10 months ago
BMRN
AnalystsMitchell S. KapoorMitchell S. Kapoor's Stock Forecasts
AnalystsMitchell S. Kapoor
Sectors:
Industries:
Analyst Ranking
Top 7%
#347 out of 5502 analysts
Average Return
+17.08%
Win Rate
58%83 out of 144
Risk vs Reward
Poor
Good
Mitchell S. Kapoor's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Oruka Therapeutics IncORKA | +638.75% | $15.25 | $112.66 | 2025-08-18 - 2026-08-17 | Buy |
Alumis IncALMS | +420.96% | $4.39 | $22.87 | 2025-08-14 - 2026-05-15 | Buy |
Oruka Therapeutics IncORKA | +230.79% | $27.70 | $91.63 | 2025-10-27 - 2026-09-02 | Buy |
Boundless Bio IncBOLD | +154.05% | $1.11 | $2.82 | 2025-08-11 - 2026-08-10 | Buy |
Neurogene IncNGNE | +126.31% | $16.95 | $38.36 | 2026-01-13 - 2026-09-02 | Buy |
Mitchell S. Kapoor Analyst Color
Get additional color on Mitchell S. Kapoor's coverage of popular stocks
a year ago
BMRN
Mitchell S. Kapoor's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Halozyme Therapeutics IncHALO | 9 | Buy | $115.00 | +4.87% | Reiterates | 2 days ago |
Alumis IncALMS | 8 | Buy | $15.00 | +32.04% | Upgrades | 2 days ago |
Biomarin Pharmaceutical IncBMRN | 10 | Hold | $60.00 | -9.68% | Maintains | 4 days ago |
Ascendis Pharma AASND | 2 | Buy | $344.00 | +28.69% | Maintains | 4 days ago |
Ionis Pharmaceuticals IncIONS | 13 | Buy | $115.00 | +87.51% | Reiterates | 4 days ago |
Scribe Therapeutics IncSCTX | 1 | Buy | $60.00 | +94.17% | Initiates Coverage On | 4 days ago |
Generate Biomedicines IncGENB | 3 | Buy | $30.00 | +83.60% | Maintains | 7 days ago |
Summit Therapeutics IncSMMT | 13 | Hold | N/A | N/A | Reiterates | 9 days ago |
Incyte CorpINCY | 15 | Buy | $150.00 | +17.19% | Reiterates | 15 days ago |
Korro Bio IncKRRO | 5 | Buy | $15.00 | +29.09% | Reiterates | 15 days ago |
Atrium Therapeutics IncRNA | 2 | Buy | $25.00 | +77.81% | Reiterates | 21 days ago |
Neurogene IncNGNE | 6 | Buy | $65.00 | +69.45% | Maintains | 23 days ago |
Avalo Therapeutics IncAVTX | 5 | Buy | $30.00 | +55.12% | Maintains | a month ago |
Oruka Therapeutics IncORKA | 7 | Buy | $120.00 | +31.88% | Reiterates | a month ago |
Legend Biotech CorpLEGN | 7 | Buy | $65.00 | +198.85% | Reiterates | a month ago |
Damora Therapeutics IncDMRA | 2 | Buy | $45.00 | +59.69% | Reiterates | a month ago |
Meiragtx Holdings PLCMGTX | 2 | Buy | $20.00 | +43.16% | Reiterates | 2 months ago |
Crispr Therapeutics AgCRSP | 2 | Buy | $80.00 | +41.62% | Reiterates | 2 months ago |
Evommune IncEVMN | 5 | Hold | N/A | N/A | Downgrades | 2 months ago |
Intellia Therapeutics IncNTLA | 9 | Buy | $25.00 | +95.92% | Reiterates | 3 months ago |
Lyell Immunopharma IncLYEL | 4 | Buy | $45.00 | +200.90% | Reiterates | 3 months ago |
Kyverna Therapeutics IncKYTX | 5 | Buy | $25.00 | +199.40% | Reiterates | 3 months ago |
Crescent Biopharma IncCBIO | 4 | Hold | N/A | N/A | Downgrades | 3 months ago |
Tyra Biosciences IncTYRA | 3 | Buy | $45.00 | +81.01% | Reiterates | 4 months ago |
Cartesian Therapeutics IncRNAC | 2 | Buy | $25.00 | +175.33% | Maintains | 4 months ago |
Cytomx Therapeutics IncCTMX | 3 | Buy | $11.00 | +198.91% | Maintains | 4 months ago |
Century Therapeutics IncIPSC | 1 | Buy | $5.00 | +139.23% | Maintains | 4 months ago |
Sarepta Therapeutics IncSRPT | 5 | Sell | $5.00 | -78.25% | Reiterates | 5 months ago |
Palisade Bio IncPALI | 1 | Buy | $7.00 | +242.30% | Initiates Coverage On | 5 months ago |
Lexeo Therapeutics IncLXEO | 4 | Buy | $10.00 | +109.21% | Maintains | 8 months ago |
Instil Bio IncTIL | 4 | Hold | N/A | N/A | Downgrades | 8 months ago |
Editas Medicine IncEDIT | 2 | Buy | $5.00 | +62.34% | Reiterates | a year ago |
Metagenomi Therapeutics IncMGX | 1 | Buy | $7.00 | N/A | Reiterates | a year ago |
Zura Bio LtdZURA | 1 | Hold | $2.00 | N/A | Maintains | a year ago |
Boundless Bio IncBOLD | 1 | Buy | $4.00 | N/A | Maintains | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.